- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs
New Studies Grow XARELTO® Clinical Development Program to More Than 275,000 Patients
Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing
Enhanced Offering to Enable ‘Dynamic Monitoring’ in Cancer Research
Janssen Affiliate Cilag GmbH International Acquires Covagen AG
Clinical Candidate COVA 322 and FynomAb® Technology Platform Further Strengthen Immunology Portfolio and Capabilities
U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes
In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone
Janssen Launches Online Healthy Minds Video Series
Promotes Knowledge of Brain Disorders and Encourages Anti-Stigma Efforts
Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C
Study evaluated interferon-free combination in treatment-naïve and prior null-responder patients with all stages of liver fibrosis, including cirrhosis
IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p
Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival
Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies
Submission based on first head-to-head study vs. oral treatments in real world context